Ahmet Adil Esen
Research Interests
Ahmet Adil Esen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Muhammed Selcuk Ozer
Faculty of Medicine, Department of Urology, Dokuz Eylul University, Izmir, Turkey
2 shared publications Ozan Bozkurt
DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ
2 shared publications- Volkan Sen
Department of Urology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkiye
2 shared publications - Canet Incir
Department of Medical Pharmacology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
1 shared publication - Ege Alper Sarıkaya
Faculty of Medicine, Department of Urology Turkey, Dokuz Eylül University, İzmir, Turkey.
1 shared publication - Gül Ergör
Dokuz Eylul University, School of Medicine
1 shared publication
Latest Publications
- 29 April 2026
- Published by Dokuz Eylul Universitesi Tip Fakultesi Dergisi in Developments and Experiments in Health and Medicine
- Vol. 40 (2) , 156-164
Impact of metformin on recurrence and progression in nonmuscle invasive bladder cancer
Purpose: To investigate the effect of metformin use on recurrence and progression in nonmuscle invasive bladder cancer patients (NMIBC). Material method: Patients who underwent primary transurethral bladder tumor resection between 2016 and 2020 were screened. Only patients with NMIBC were included in the study. The patients were divided into two groups according to the use of metformin and the groups were compared in terms of recurrence and progression. Results: According to inclusion criteria 176 NIMBC patients were included in the study. Metformin use was detected in 37 patients. The demographic characteristics and follow-up times of the patients were similar between the user and nonuser groups. Recurrence was detected in only 8.1% of the metformin user group. On the other hand, the recurrence rate was 32.4% in the nonuser group. There was no progression in the metformin user group. But in the non-user group progression rate was 8,6%. Conclusion: In our study, we found that recurrence and progression rates were lower in metformin-using patients. Prospective randomized trials are needed to understand the effects of metformin use on bladder cancer.
- 29 April 2026
- Published by Dokuz Eylul Universitesi Tip Fakultesi Dergisi in Developments and Experiments in Health and Medicine
- Vol. 40 (2) , 156-164
Impact of metformin on recurrence and progression in nonmuscle invasive bladder cancer
Purpose: To investigate the effect of metformin use on recurrence and progression in nonmuscle invasive bladder cancer patients (NMIBC). Material method: Patients who underwent primary transurethral bladder tumor resection between 2016 and 2020 were screened. Only patients with NMIBC were included in the study. The patients were divided into two groups according to the use of metformin and the groups were compared in terms of recurrence and progression. Results: According to inclusion criteria 176 NIMBC patients were included in the study. Metformin use was detected in 37 patients. The demographic characteristics and follow-up times of the patients were similar between the user and nonuser groups. Recurrence was detected in only 8.1% of the metformin user group. On the other hand, the recurrence rate was 32.4% in the nonuser group. There was no progression in the metformin user group. But in the non-user group progression rate was 8,6%. Conclusion: In our study, we found that recurrence and progression rates were lower in metformin-using patients. Prospective randomized trials are needed to understand the effects of metformin use on bladder cancer.
- 1 March 2023
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 10 (1) , 36-42
Efficacy and Safety of a 5-Alpha Reductase Inhibitor, Dutasteride, Added to Bacillus Calmette-Guérin Immunotherapy for Prevention of Recurrence and Progression of Intermediate- and High-Risk Non- Muscle Invasive Bladder Cancer: A Single-Arm, Phase 2 Clinical Trial
- 1 March 2023
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 10 (1) , 36-42
Efficacy and Safety of a 5-Alpha Reductase Inhibitor, Dutasteride, Added to Bacillus Calmette-Guérin Immunotherapy for Prevention of Recurrence and Progression of Intermediate- and High-Risk Non- Muscle Invasive Bladder Cancer: A Single-Arm, Phase 2 Clinical Trial